Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. (Q35023525)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

review article

1 reference

title

Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Elżbieta Tryniszewska

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author name string

Genoveffa Franchini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Janos Nacsa

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

language of work or name

English

0 references

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

20 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

A52-60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Immune restoration with antiretroviral therapies: implications for clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Changes in Frequency of HIV‐1–Specific Cytotoxic T Cell Precursors and Circulating Effectors after Combination Antiretroviral Therapy in Children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV and AIDS. Gap between biology and reality in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Crystalluria and urinary tract abnormalities associated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Studies of body composition and fat distribution in HIV-infected and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Structured treatment interruptions for the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Emergence of Cytotoxic T Lymphocyte Escape Mutants following Antiretroviral Treatment Suspension in Rhesus Macaques Infected with SIVmac251

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Therapeutic vaccines in HIV.1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

The simian immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Diagnosing primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Titration and characterization of two rhesus-derived SIVmac challenge stocks

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Failure to expand influenza and tetanus toxoid memory T cells in vitro correlates with disease course in SIV infected rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Impairment of Gag-specific CD8(+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses r

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Differential expression of interleukin-2 and gamma interferon in human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Skewed maturation of memory HIV-specific CD8 T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV preferentially infects HIV-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Preferential S phase entry and apoptosis of CD4(+) T lymphocytes of HIV-1-infected patients after in vitro cultivation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Effect of phorbol myristate acetate on T cell colony formation, interleukin-2 (IL-2) receptor expression and IL-2 production by cells from patients at all stages of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Reduction of IFN-g and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Response of naïve and memory CD8+ T cells to antigen stimulation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900388-2

7 January 2021

10.1016/S0264-410X(02)00388-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12477429%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference